ACADIA Pharmaceuticals Inc. has grown revenue 27% a year over three years and 20% a year over five. Revenue growth, 3-year annual rate: +27% (Biotechnology median +17%). Revenue growth, 5-year rate: +20%, growth has picked up over the last three years. Years of annual history on file: 17, FY2009 to FY2025, as filed.

ACADACADIA Pharmaceuticals Inc.

Healthcare

$19.78-19% 1Y

$19.78

$19.5752 weeks$30.58

Is it growing?

Mixed

Neither accelerating nor breaking down: revenue growing +12% year on year and earnings up +68% year on year, but operating margin narrowing (−15.6 points).

2 good, 1 to watch

Revenue trend+12% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +20% a year.

Earnings trend+68% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing faster than revenue, so margins or the share count are helping.

Margin direction−15.6 points operating

Trailing-twelve-month operating margin, 7.4% now against 23.0% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Revenue growth, 3 yearstop 7% of the market

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is ACAD growing?

ACADIA Pharmaceuticals Inc. has grown revenue 27% a year over three years and 20% a year over five.

+27%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +20%
Revenue growth, 5-year rate · +27% over three · growth has picked up over the last three years
Years of annual history on file: 17
Years of annual history on file · FY2009 to FY2025, as filed

Details›